- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
ChemoCentryx is a biotechnology business based in the US. ChemoCentryx shares (CCXI) are listed on the NASDAQ and all prices are listed in US Dollars. ChemoCentryx employs 178 staff and has a trailing 12-month revenue of around $37.3 million.
Our top picks for where to buy ChemoCentryx stock
- Trade $0 commission stocks, ETFs, and options with as little as $1
- After-hours trading available
- Earn 4.5% interest on uninvested cash with Gold
- 24/7 customer support
- $0 commission trading
- Instant withdrawals with a 1.75% fee
- Supports 250+ cryptocurrencies
- High-yield account earns up to 4.65% APY
How to buy ChemoCentryx stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – CCXI. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy ChemoCentryx stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
ChemoCentryx stock price (NASDAQ: CCXI)
Use our graph to track the performance of CCXI stocks over time.ChemoCentryx shares at a glance
52-week range | $0.00 - $0.00 |
---|---|
50-day moving average | $51.50 |
200-day moving average | $31.84 |
Wall St. target price | $52.00 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-2.01 |
Is it a good time to buy ChemoCentryx stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
ChemoCentryx financials
Revenue TTM | $37.3 million |
---|---|
Gross profit TTM | $-51,068,000 |
Return on assets TTM | -18.55% |
Return on equity TTM | -46.96% |
Profit margin | 0% |
Book value | $3.32 |
Market Capitalization | $3.7 billion |
TTM: trailing 12 months
ChemoCentryx share dividends
We're not expecting ChemoCentryx to pay a dividend over the next 12 months.
ChemoCentryx share price volatility
Over the last 12 months, ChemoCentryx's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ChemoCentryx's is 1.2296. This would suggest that ChemoCentryx's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
ChemoCentryx overview
ChemoCentryx, Inc. , a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc.
Frequently asked questions
nullWhat percentage of ChemoCentryx is owned by insiders or institutions?
Currently 12.008% of ChemoCentryx shares are held by insiders and 84.394% by institutions. How many people work for ChemoCentryx?
Latest data suggests 178 work at ChemoCentryx. When does the fiscal year end for ChemoCentryx?
ChemoCentryx's fiscal year ends in December. Where is ChemoCentryx based?
ChemoCentryx's address is: 835 Industrial Avenue, San Carlos, CA, United States, 94070 What is ChemoCentryx's ISIN number?
ChemoCentryx's international securities identification number is: US16383L1061 What is ChemoCentryx's CUSIP number?
ChemoCentryx's Committee on Uniform Securities Identification Procedures number is: 16383L106
More guides on Finder
-
Robinhood Now Let’s You Trade on the Outcome of the Presidential Election; Joining Kalshi and others.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
Trading for Beginners: 9 Best Trading Platforms to Get Started
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
SoFi Invest vs. Robinhood
Compare pros, cons, research tools and reviews for these two trading platforms.
-
10 Best Stock Apps of 2024 to Elevate Your Mobile Trading
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
-
10 Best Brokerage Accounts for Trading and Investing in 2024
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to Invest $10K
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
-
How to Invest $20K: 8 Ways to Maximize Earnings
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
-
Robinhood Review 2024: IRA Match and No Commissions
A deep dive into the highlights and limitations of Robinhood.
Ask a question